the EL deal was done when Qbrexza had been on market for about a year, and included Lebrikizumab that Dermira had paid Roche $80M upfront plus future payments owed to Roche $40M for starting phase 3 trial, up to $210M for regulatory/territory milestones, $1.025B upon achieving net sales thresholds. So hard to know what value Qbrexza had in that deal.
the EL deal was done when Qbrexza had been on market for about a...
-
- There are more pages in this discussion • 3,611 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.5¢ | $960.8K | 2.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 527761 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 280228 | 15 |
View Market Depth
| Last trade - 14.29pm 30/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |